IF = 24.5 | Jiyan Biotech Contributes to Research Achievements Published in the International Academic Journal Gut

On April 25th, Dr. Liu Jinxia, an associate chief physician in the Department of Gastroenterology at Affiliated Hospital of Nantong University, collaborated with the team led by Prof. Rajiv Jalan from University College London (UCL) and Royal Free Hospital in the UK. They published an original research article titled "Clinical, experimental and pathophysiological effects of Yaq - 001: a non - absorbable, gut - restricted adsorbent in models and patients with cirrhosis" in Gut, a top journal in gastroenterology (IF: 24.5). Liu Jinxia is the first author of this article. The article proposes a new concept of using the novel activated carbon beads Yaq - 001 for the prevention and treatment of cirrhosis and acute - on - chronic liver failure. (Reposted from the official website of Affiliated Hospital of Nantong University)

In - vivo Experiments in Mice

The research team developed a novel non - absorbable, gut - restricted activated carbon bead, Yaq - 001, which can rapidly adsorb endotoxin in vitro. By establishing different models of cirrhosis and acute - on - chronic liver failure and orally administering Yaq - 001 for 2 or 6 weeks, the team found that Yaq - 001 treatment could significantly reduce liver injury, the progression of liver fibrosis, portal hypertension, renal function impairment, and the mortality rate of acute - on - chronic liver failure.

In addition, Yaq - 001 treatment could markedly alleviate endotoxemia, hyperammonemia, and systemic inflammatory response in different animal models. Multi - organ transcriptomics indicated that Yaq - 001 could regulate inflammation, cell death, and senescence in organs such as the liver, brain, kidney, and intestine. 16s sequencing and metabolomic analysis showed that Yaq - 001 could affect the composition of gut microbiota and their metabolites.

In - vitro Organoid Experiments

Meanwhile, the research team used Jiyan Biotech's mouse intestinal organoid culture system to establish mouse intestinal organoids and conducted an intestinal organoid inversion experiment. They co - cultured the fecal water of mice in different model groups with mouse intestinal organoids. The results indicated that Yaq - 001 could directly reduce the barrier permeability of intestinal organoids.

Figure 5. Effects of Yaq - 001 on the permeability of small intestinal organoids. A. Culture and polarity inversion (apical - out) of small intestinal organoids from C57BL/6 mice; F - actin was used to label the microvilli of intestinal epithelial cells. B. The inverted organoids differentiated and matured under suspension culture conditions and expressed the goblet cell marker (MUC2). C. Fecal water from different treatment groups with liver injury was co - cultured with the organoids, and Yaq - 001 could reduce the barrier permeability of intestinal organoids (Liu J, et al. Gut 2024;0:1–15. doi:10.1136/gutjnl - 2023 - 330699).

*Mouse Intestinal Organoids Kit (CAT: MOCK002, provided by Jiyan Biotech)

Get more information: https://en.jiyanbio.com/product/766.html

*CS Well 600, High-throughput 3D organoid culture microarray (courtesy of JIBS)

Clinical Trials

The research team further conducted a multicenter, double - blind, randomized, placebo - controlled clinical trial in 28 cirrhotic patients, initially clarifying the safety and tolerance of Yaq - 001 in clinical trials.

The publication of this research achievement provides a strong preliminary foundation for the clinical translation of Yaq - 001 for cirrhotic patients globally. This achievement also won the TOP poster at the 2023 European Association for the Study of the Liver (EASL) Annual Meeting.

Gut is a world - leading journal in gastroenterology and hepatology. It enjoys a high reputation for publishing top - tier clinical research on the digestive tract, liver, biliary tract, and pancreas, providing the latest, authoritative, and clinically - oriented reports in all fields of gastroenterology and hepatology.

The publication of this research achievement also successfully reveals the consistency of organoids as an innovative in - vitro model with in - vivo mouse models and clinical trials, adding new impetus to the development and application of organoids.

Adhering to the concept of "assisting undertakings and delving deep into research", Jiyan Biotech is dedicated to the development of high - quality innovative products. With a rigorous attitude of being practical, applying research to practice, pioneering, and striving for excellence, it serves the scientific research cause in China and provides high - quality products and services for research, translation, and application in the fields of human health and life sciences!

Jiyan Biotech's Mouse Organoids and Kit Series Products

Immunofluorescence Identification of Mouse Organoids

The image displays a selection of products. For comprehensive details and further inquiries, please feel free to contact us.

About Jiyan Biotech

Article Link:

https://gut.bmj.com/content/early/2024/04/24/gutjnl-2023-330699.long doi: 10.1136/gutjnl-2023-330699.

References:

1. Jinxia Liu, et al. Clinical, experimental and pathophysiological effects of Yaq-001: a non-absorbable, gut-restricted adsorbent in models and patients with cirrhosis. Gut. 2024 Apr 25:gutjnl-2023-330699. doi: 10.1136/gutjnl-2023-330699. 

2. Stijn Aaron den Daas, et al. A permeability assay for mouse intestinal organoids. STAR Protoc. 2022.

3. Puschhof J, et al.  Intestinal organoid cocultures with microbes. Nat Protoc. 2021 Oct;16(10):4633-4649. 

4. Co JY, et al.  Controlling Epithelial Polarity: A Human Enteroid Model for Host-Pathogen Interactions. Cell Rep. 2019 Feb 26;26(9):2509-2520.e4.